Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[HIV-lipodystrophy syndrome].

S Mauss1, G Schmutz

  • 1Gemeinschaftspraxis für Gastroenterologie, Hämatologie und internistische Onkologie, Düsseldorf.

Medizinische Klinik (Munich, Germany : 1983)
|August 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zeitschrift fur Gastroenterologie·2020
Same author

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.

Alimentary pharmacology & therapeutics·2018
Same author

Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?

HIV medicine·2018
Same author

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.

Journal of viral hepatitis·2017
Same author

Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.

Alimentary pharmacology & therapeutics·2017
Same author

Chronic hepatitis C patients prior to broad access to interferon-free treatments in Germany.

Zeitschrift fur Gastroenterologie·2016
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014
See all related articles

HIV-associated lipodystrophy syndrome, characterized by fat redistribution and metabolic changes, increasingly affects patients on antiretroviral therapy. Management involves modifying treatment and addressing symptoms to mitigate long-term cardiovascular risks.

Area of Science:

  • Endocrinology
  • Infectious Diseases
  • Metabolic Syndrome

Context:

  • Growing incidence of HIV-associated lipodystrophy syndrome in patients undergoing antiretroviral therapy (ART).
  • Syndrome characterized by peripheral fat loss, potential visceral fat accumulation, dyslipidemia, and glucose metabolism disturbances.

Purpose:

  • To review the clinical findings, pathogenesis, and treatment of HIV-associated lipodystrophy syndrome.
  • To highlight the association between ART and the development of lipodystrophy.
  • To discuss the long-term implications and management strategies.

Summary:

  • HIV-associated lipodystrophy syndrome presents with fat redistribution (face, extremities, buttocks), metabolic abnormalities including hyperlipidemia and disturbed glucose metabolism.
  • Risk factors include ART duration, drug type, low CD4 count, older age, and pre-existing metabolic issues.

Related Experiment Videos

  • While ART offers short-term benefits, long-term cardiovascular risks from metabolic disturbances necessitate treatment modification and symptomatic management.

    • Impact:

    • Informs clinicians about the multifaceted nature of HIV-associated lipodystrophy syndrome.
    • Emphasizes the need for vigilant monitoring of metabolic changes in patients on ART.
    • Guides therapeutic strategies to balance viral suppression with metabolic health and reduce mortality.